|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 2 | APOE genotype makes a small contribution to warfarin dose requirements显示文摘 | Sconce EA Daly AK Khan TI | 2006 | Pharmacogenet Genomics2006，16，8： | 1 |
| 3 | The toxic effects of sodium fluoride on the reproductive system of male rats显示文摘 | Gupta RS Khan TI Agrawal D | | 0，，9： | 1 |
| 4 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 5 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon war- farin dose requirements: proposal for a new dosing regimen 显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 6 | APOE genotype makes a small contribution to warfarin dose requirements显示文摘 | Sconce EA Daly AK Khan TI | 2006 | Pharmacogenet Ge- nomics2006，16，8： | 1 |
| 7 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 8 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 9 | Contribution of age,body size,and CYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP Frearson R Kesteven P Wood P | 2004 | Clin Pharmacol Ther2004，75，： | 1 |
| 10 | Contribution of age,boby size, and CYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，3： | 1 |
| 11 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen 显示文摘 | SCONCE EA KHAN TI WYNNE HA | 2005 | Blood2005，106，7： | 1 |
| 12 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 13 | The im- pact of CYP2C9 and VKORC1 genetic polymor- phism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regi men显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 14 | Contribution of age, body size, andCYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP | 2004 | Clin PhamacolTher2004，75，： | 1 |
| 15 | The impact of CYP2C9 and VKORC1 genetic poly-morphism and patient characteristics upon warfarin dose requireme, nts: proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，： | 1 |
| 16 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen 显示文摘 | Sconece EA Khan Ti Wynne HA | 2010 | Blood2010，106，7： | 1 |
| 17 | Contribution of age,body size, and CYP2C9 genotype to anticoagulant response to warfarin 显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，3： | 1 |
| 18 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon war- farin dose requirements:proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA | 2005 | Blood2005，106，7： | 1 |
| 19 | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin 显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，： | 1 |
| 20 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA Avery P Monkhouse L King BP | 2005 | Blood2005，106，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员